Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis
The January 2019 issue of Clinical Chemistry is devoted to the area of men's health. Aside from non-melanoma skin cancer, prostate cancer is the most common cancer among men in the United States. It is remarkable that even though the introduction of prostate specific antigen, or PSA, into U.S. clinical practice occurred over three decades ago, researchers and clinicians are still debating its value for prostate cancer screening. In that special issue, Dr. Andrew Vickers published an Opinion article titled, "Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis."
Available Results
Generated results are saved to the knowledge database for reuse and search.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.